Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OlympusOCPNF 77 Return-on-Tangible-Asset is 8.18% as of Mar. 2026, which is 20% above its 10-year median of 6.80. GuruFocus rates OCPNF with a GF Score™ of 77/100 and a GF Value™ of $16.27 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Olympus ranks better than 68.3% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Olympus's annualizedNet Income for the quarter that ended in Mar. 2026 was $626 Mil. Olympus's average total tangible assets for the quarter that ended in Mar. 2026 was $7,642 Mil. Therefore, Olympus's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 8.18%.
The historical rank and industry rank for Olympus's Return-on-Tangible-Asset or its related term are showing as below:
OCPNF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.04 Med: 6.8 Max: 19.62
Current: 5.84
During the past 13 years, Olympus's highest Return-on-Tangible-Asset was 19.62%. The lowest was 1.04%. And the median was 6.80%.
OCPNF's Return-on-Tangible-Asset is ranked better than 68.3% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs OCPNF: 5.84
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Olympus Return-on-Tangible-Asset Related Terms
Olympus Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Olympus's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCPNF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Olympus's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olympus Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Olympus's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 8.18% mean?
Olympus (OCPNF) has a Return-on-Tangible-Asset of 8.18% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Olympus and its competitors. This is 20% above median its historical median of 6.80. Over the past decade, Olympus' Return-on-Tangible-Asset has ranged from 1.04 to 19.62. According to the industry distribution chart, Olympus ranks #271 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Olympus' Return-on-Tangible-Asset too high?
Olympus' current Return-on-Tangible-Asset of 8.18% is 20% above median its 10-year median of 6.80. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 19.62. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Olympus' value of 8.18% is 1219.4% above this industry median. Based on the distribution chart, Olympus ranks #271 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Olympus has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #271 out of 855 companies for Return-on-Tangible-Asset. This puts Olympus in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.62. Olympus' value of 8.18% is 1219.4% above this benchmark. Historically, Olympus' own Return-on-Tangible-Asset has ranged from 1.04 to 19.62 over the past decade. While the company's 10-year median is 6.80 vs. the industry median of 0.62, Olympus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olympus's current Return-on-Tangible-Asset of 8.18% is 1219.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Olympus and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olympus's current Return-on-Tangible-Asset is 8.18%, which is 20% above median its own 10-year median of 6.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (OCPNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $16.27, compared to a current price of $11.00 — trading 32.4% below its estimated fair value. The current Return-on-Tangible-Asset is 8.18%, which is 20% above median its 10-year median of 6.80 and 1219.4% above the Medical Devices & Instruments industry median of 0.62. Olympus' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Olympus (OCPNF), the current Return-on-Tangible-Asset is 8.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Olympus (OCPNF) Overvalued in 2026?
Based on GuruFocus' analysis, Olympus stock appears to be undervalued.
The current stock price of $11.00 is trading 32.4% below its estimated GF Value™ of $16.27.
GuruFocus considers Olympus to be Significantly Undervalued.
Key valuation signals for OCPNF:
Return-on-Tangible-Asset: 8.18% (20% above median its 10-year median of 6.80)
GF Value™: $16.27 vs. price of $11.00 (32.4% below fair value)
Industry Position: 1219.4% above the Medical Devices & Instruments median (#271 of 855)
No single metric tells the full story. See the OCPNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
77GF Score
Get the complete analysis for OCPNF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCPNF has been successfully added to your 
